Vaccibody AS is pleased to announce that the U.S. Patent Office has Issued patent No. US 8,932,603 B2 covering the Vaccibody format which can be described as homodimeric modular constructs targeting vaccines to antigen presenting cells designed to increase the immune system’s antibody and T-cell responses. In December 2014 Vaccibody announced that the equivalent patent was granted by the European Patent Office.
This patent protects Vaccibody’s platform technology on which the company has based its lead drug candidate VB10.16 as well as the previously announced license agreement with the Phibro Animal Health Corporation, covering vaccines for poultry. The technology allows for the development of new and more efficient vaccines as well as new versions of existing vaccines with a need for improved efficacy. It lends itself to therapeutic vaccines, such as cancer vaccines, as well as prophylactic (preventive) vaccines against infections. The company will utilize its technology platform to develop human and veterinary Vaccibody vaccines both through developing its own drug pipeline as well as offering the pharmaceutical industry exclusive licenses to the technology platform.
The company’s lead product, VB10.16, is being developed as a DNA vaccine to prevent the development of and treat HPV16 induced pre-malignancies and malignancies. The first in man clinical trial is currently in late stage preparations. This initial clinical evaluation will aim to characterise the safety and immunogenicity of VB10.16 in HPV16 infected women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3).
Tom Pike, Acting CEO of Vaccibody, commented: “This patent is a cornerstone in the protection of our novel technology platform, which is the discovery engine of Vaccibody’s own pipeline. We expect that it will also provide the basis for additional strategic partnerships with pharmaceutical companies in the future. Although Vaccibody has filed a number of additional patent applications offering several layers of protection to our pipeline and technology, this patent family is the first and thus represents an important milestone for the company.”
About Vaccibody AS
Vaccibody is a vaccine company dedicated to the discovery and development of novel prophylactic and therapeutic vaccines which target cancer and infectious diseases, for human and veterinary use. Vaccibody’s lead program is focused on VB10.16, a therapeutic DNA vaccine against HPV induced pre-malignancies and malignancies. A first-in-man study currently in preparation will evaluate the safety and immunogenicity of VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3) and is planned to be initiated early 2015.
Contact:
Tom Pike
Chairman & Acting CEO
+47 915 19 652
tpike@vaccibody.com
